5-amino-1mq nnmt inhibitor obesity study Comment “curious” for the full

Semaglutide Semaglutide was originally developed as a medication to help regulate insulin production in people with Type 2 Diabetes

Suitable for adults, it is administered under medical supervision via intramuscular or intravenous routes

It has a key role in the normal functioning of our neurological system and helps in the formation of healthy red blood cells

Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy